HOW ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IS CHANGING SPUTUM CULTURE COLLECTION FOR PEOPLE WITH CYSTIC FIBROSIS

被引：0
|
作者：
Pai, S. [1 ]
Villagomez, K. [2 ]
Dorsett, S. [3 ]
Guthrie, C. P. [4 ]
机构：
[1] Dell Childrens Med Ctr Cent Texas, Pediat CF Ctr Specialty Care, Austin, TX USA
[2] Ascens Seton Med Ctr Austin, Adult CF Ctr Cent Texas, Austin, TX USA
[3] Univ Hlth Syst, CF Ctr, San Antonio, TX USA
[4] UT Hlth Tyler North Campus, Cyst Fibrosis Ctr & Pulm Clin, Tyler, TX USA
来源：
PEDIATRIC PULMONOLOGY | 2020年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
569
引用
收藏
页码：S260 / S260
页数：1
相关论文
共 50 条
  • [21] A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis
    Kinsey, Laura
    Winterbottom, Hannah
    Hudson, Lydia
    Lal, Simon
    Jones, Andrew M.
    Burden, Sorrel
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2025,
  • [22] ADHERENCE TO NEBULISED THERAPIES IN PEOPLE WITH CYSTIC FIBROSIS STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (KAFTRIO)
    Howell, I. B.
    Tugwell, A.
    Bhaskaran, D.
    Bell, N. J.
    THORAX, 2021, 76 : A40 - A40
  • [23] Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis
    Westhoelter, D.
    Schumacher, F.
    Wuelfinghoff, N.
    Sutharsan, S.
    Strassburg, S.
    Kleuser, B.
    Horn, P. A.
    Reuter, S.
    Gulbins, E.
    Taube, C.
    Welsner, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [24] MEDICATION ACCESS BARRIERS FOR ELEXACAFTOR/TEZACAFTOR/IVACAFTOR-ELIGIBLE PEOPLE WITH CYSTIC FIBROSIS
    Dieni, O.
    Ryan, L.
    Stocks, A.
    Erdo, J.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S359 - S359
  • [25] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [26] Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis
    Furstova, Eva
    Dousova, Tereza
    Beranek, Jakub
    Libik, Malgorzata
    Fila, Libor
    Modrak, Martin
    Cinek, Ondrej
    Macek, Milan, Jr.
    Drevinek, Pavel
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : 243 - 245
  • [27] Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis
    Simon, Graeber Y.
    Annalisa, Addante
    MIrjam, Voeller
    Laura, Schaupp
    Kerstin, Fentker
    Markus, Bardua
    Aditi, Kuppe
    Julia, Duerr
    Linus, Piehler
    Jobst, Roehmel
    Stephanie, Thee
    Marieluise, Kirchner
    Matthias, Ziehm
    Daniel, Lauster
    Rainer, Haag
    Michael, Gradzielski
    Mirjam, Stahl
    Philipp, Mertins
    Sebastien, Boutin
    Marcus, Mall A.
    KLINISCHE PADIATRIE, 2023, 235 (02): : 118 - 119
  • [28] Elexacaftor/tezacaftor/ivacaftor treatment corrects the salt-losing phenotype in people with cystic fibrosis
    Leipziger, Jens
    Svendsen, Samuel
    Rousing, Amalie Quist
    Jensen-Fangel, Soren
    Bandulik, Sascha
    Warth, Richard
    Sorensen, Mads Vaarby
    Jeppesen, Majbritt
    Berg, Peder
    ACTA PHYSIOLOGICA, 2023, 239
  • [29] The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis
    Hergenroeder, Georgene E.
    Faino, Anna
    Bridges, Gracia
    Bartlett, Lauren E.
    Cogen, Jonathan
    Green, Nicole
    Mcnamara, Sharon
    Nichols, David P.
    Ramos, Kathleen J.
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (06) : 1048 - 1053
  • [30] Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis
    Casey, Michelle
    Gabillard-Lefort, Claudie
    McElvaney, Oisin F.
    McElvaney, Oliver J.
    Carroll, Tomas
    Heeney, Ronan C.
    Gunaratnam, Cedric
    Reeves, Emer P.
    Murphy, Mark P.
    McElvaney, Noel G.
    THORAX, 2023, 78 (08) : 835 - 839
12345